Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Rhea-AI Summary

Agios Pharmaceuticals (Nasdaq: AGIO), a leader in cellular metabolism and PK activation therapies for rare diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company is scheduled to present on Wednesday, September 18, 2024, at 10:20 a.m. ET.

Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Agios' website at www.agios.com. For those unable to attend the live event, a replay of the webcast will be available on the company's website for at least two weeks following the presentation, ensuring widespread access to the information shared during the conference.

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:

Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Dan Budwick
1AB
dan@1abmedia.com  

FAQ

When is Agios Pharmaceuticals (AGIO) presenting at the 2024 Cantor Global Healthcare Conference?

Agios Pharmaceuticals (AGIO) is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET.

How can I watch Agios Pharmaceuticals' (AGIO) presentation at the 2024 Cantor Global Healthcare Conference?

You can watch a live webcast of Agios Pharmaceuticals' (AGIO) presentation by accessing the 'Events & Presentations' section in the Investors area of the company's website at www.agios.com.

Will there be a replay available of Agios Pharmaceuticals' (AGIO) presentation at the 2024 Cantor conference?

Yes, a replay of the webcast will be archived on Agios Pharmaceuticals' (AGIO) website for at least two weeks following the presentation at the 2024 Cantor Global Healthcare Conference.

What is Agios Pharmaceuticals' (AGIO) focus in the healthcare industry?

Agios Pharmaceuticals (AGIO) is a leader in cellular metabolism and PK activation, focusing on pioneering therapies for rare diseases.